Companies · Biotech / Pharma

Imago BioSciences, Inc.

San Carlos · Biotech / Pharma · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Imago BioSciences, Inc. — recommendation, valuation, rhythm, risks.
$137.5M
Total raised · real
3
Rounds
4.7×
Latest step-up
Top 5%
Sector rank · raised
Series C
Latest stage · inferred · Thu Nov 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Imago BioSciences, Inc. has raised $137M over 3 rounds; too few niche peers to rank its valuation yet.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Dormant
  • Last raise 5.6 yr ago; this sector typically re-raises about every 15 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Imago BioSciences, Inc. is one of 227 Biotech / Pharma companies tracked from San Carlos. By capital raised it ranks among the largest (ahead of 96% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
28
Investors (latest)
2020-11-12
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries A · 2014-10-30 Raised $8.8M (real) Modeled valuation $296M (est)$8.8M$296MSeries A2014Series C · 2014-10-30 Raised $40M (real) Modeled valuation $1.5B (est)$40M$1.5BSeries C2014Series C · 2019-03-15 Raised $17M (real) Modeled valuation $645M (est)$17M$645MSeries C2019Series C · 2020-11-12 Raised $80M (real) Modeled valuation $2.7B (est)$80M$2.7BSeries C2020+$40M+$17M+$80MCumulative $146M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$8.8M · 2014
Series C$40.5M · 2014no Series B on file
Series C extension$17.0M · 2019
Series C extension$80.0M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$2.7B
Base estimate est.
$253.7M
Conservative case
$6.7B
Upside case
$533.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Series A · modeled $295.9M · 2014-10-302014Series C · modeled $1.5B · 2014-10-30Series C · modeled $645.2M · 2019-03-15Series C · modeled $2.7B · 2020-11-122020
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
48% low · 74% high
1.44×/yr
Annual markup
1.65×/yr upside case
5.6 yr
Elapsed time used
5.6 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
24 mo
Avg between rounds
$22.8M/yr
Capital velocity
11.7 yr
On record since
2014
First round
4
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 24× above median
This company$137.5M
Sector median$5.6M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.7× above median
This company$80.0M
Sector median$48.1M
Modeled value — vs sector median (estimate, all stages) 87× above median
This company$2.7B
Sector median$30.5M

Raised more than 96% of sector peers (real $). Modeled value above 98% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful.

This companyCohort peer
$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Life Biosciences LLC · Series C Raised $123.4M · modeled $2.8B (est)BlueSphere Bio, Inc. · Series C Raised $55.6M · modeled $1.5B (est)Imago BioSciences, Inc. (this company) Raised $137.5M · modeled $2.7B (est)Imago BioSciences, Inc.
CompanyStageRaised · realValue · estvs peer med.
Life Biosciences LLCSeries C$123.4M$2.8B1.07×
Imago BioSciences, Inc. this companySeries C$137.5M$2.7B1.00×
BlueSphere Bio, Inc.Series C$55.6M$1.5B0.55×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$8.8M2014-10-30$40.2M$295.9M85%
Series C$40.5M2014-10-30$270.0M$1.5B90%
Series C$17.0M2019-03-15$113.3M$645.2M90%
Series C$80.0M2020-11-12$533.3M$2.7B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$8.8M2014-10-30
    • First recorded raise — entered as Series A.
    • 6 investors on this round.
  2. Series C$40.5M2014-10-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.6× larger than the prior — scaling up.
    • 7 investors on this round.
  3. Series C$17.0M2019-03-15
    • Raised again after 52 mo — slower than the ~15 mo sector norm.
    • Round 2.4× smaller than the prior — bridge or down round.
    • 12 investors on this round.
  4. Series C$80.0M2020-11-12
    • Raised 20 mo later, in step with the ~15 mo sector norm.
    • Round 4.7× larger than the prior — scaling up.
    • 28 investors on this round.
Intelligence
2022 ~Q4
Modeled next raise · ~24mo cadence
$240.0M
Modeled next size est.range $156.0M$384.0M
4.7×
Last step-up
$22.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Patrick J. Heron6 other2019-03
DENNIS J HENNER1 other2019-03
Dina Chaya Moghrabi1 other2019-03
Hugh Y. Rienhoff, Jr.1 other2019-03
Alan Chaya Sachs2019-03
Alan G. Sachs2014-10
Dennis G. Henner2014-10
Harish Chaya Soundararajan2020-11
Hugh Y. Rienhoff2014-10
Laura G. Eichorn2014-10
Patrick G. Heron2014-10
Robert Chaya Baltera2020-11
Registry & provenance

Imago BioSciences, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1623715
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Life Biosciences LLCBiotech / PharmaSeries C$123.4M$2.8Bsame sector · same stage
Manus Bio Inc.Biotech / PharmaSeries C$118.0M$108.4Msame sector · same stage
Coherus BioSciences, Inc.Biotech / PharmaSeries C$160.7M$258.3Msame sector · same stage
Elephas Biosciences CorpBiotech / PharmaSeries C$113.7M$560.6Msame sector · same stage
Sherlock Biosciences, Inc.Biotech / PharmaSeries C$112.8M$1.7Bsame sector · same stage
Mirum Pharmaceuticals, Inc.PharmaceuticalsSeries C$138.5M$348.3Mnetwork1 shared operator · same stage
Iterum Therapeutics LtdBiotechnologySeries C$131.4M$115.9Mnetwork1 shared operator · same stage
Pacific Biosciences Of California, Inc.Biotech / PharmaSeries C$190.3M$982.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Imago Systems, Inc.Software / TechPre-Seed$4.2M88%
Imago Rehab, Inc.Other Health CareSeed$1.1M85%
Imel Biotherapeutics, Inc.Other Health CareSeries B$222.4M83%
Octagos Health, Inc.HealthtechSeries B$195.3M83%
Alto Pharmacy Holdings, Inc.Biotech / PharmaSeries D+$3.1B82%
Aires Medical, Inc.HealthtechSeed$34.7M82%
Carbon Biosciences, Inc.Biotech / PharmaSeries B$744.8M82%
PharmaWaste Ventures, LLCBiotech / PharmaSeed$3.5M82%
Frequently asked
How much funding has Imago BioSciences, Inc. raised?
Imago BioSciences, Inc. has raised approximately $137.5M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Imago BioSciences, Inc.'s estimated valuation?
Provath's modeled valuation for Imago BioSciences, Inc. is approximately $2.7B (modeled range $253.7M–$6.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Imago BioSciences, Inc. at?
Imago BioSciences, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Thu Nov 12.
What does Imago BioSciences, Inc. do and where is it based?
Imago BioSciences, Inc. operates in the Biotech / Pharma sector, based in San Carlos.
Explore related

See where Imago BioSciences, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Imago BioSciences, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.